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Abstract: Coenzyme Q10 (CoQ10), which plays a key role in the electron transport chain by providing
an adequate, efficient supply of energy, has another relevant function as an antioxidant, acting in
mitochondria, other cell compartments, and plasma lipoproteins. CoQ10 deficiency is present in
chronic and age-related diseases. In particular, in cardiovascular diseases (CVDs), there is a reduced
bioavailability of CoQ10 since statins, one of the most common lipid-lowering drugs, inhibit the
common pathway shared by CoQ10 endogenous biosynthesis and cholesterol biosynthesis. Different
clinical trials have analyzed the effect of CoQ10 supplementation as a treatment to ameliorate
these deficiencies in the context of CVDs. In this review, we focus on recent advances in CoQ10
supplementation and the clinical implications in the reduction of cardiovascular risk factors (such
as lipid and lipoprotein levels, blood pressure, or endothelial function) as well as in a therapeutic
approach for the reduction of the clinical complications of CVD.
Keywords: coenzyme Q10; ubiquinone; ubiquinol; cardiovascular diseases
1. Introduction, CoQ10 in Cardiovascular Diseases
Coenzyme Q10 (CoQ10) was isolated by Festenstein et al. (1955) and Crane et al. (1957).
Chemically, it is a lipid-soluble, biologically active quinone with a benzoquinone ring and
an isoprenoid sidechain containing 10 residues of isoprenoid. The main function of CoQ10
is to take part in the mitochondrial electron transport chain, where it carries electrons
from complex I and II to complex III [1,2]. During the decades since it was first described,
multiple functions have been attributed to CoQ10 such as to control the cellular redox state
both by its antioxidant properties and by the generation of oxidant signals as well as a
role in proton gradient formation at the endomembrane and plasma membrane, which
contributes to control the membrane structure and phospholipid status [3–5].
The main function of CoQ10 has one important consequence for energy metabolism,
since better, more efficient electron transport in the inner membrane at the mitochondria
leads to more abundant production of ATP. This is a highly relevant factor, for instance,
for the cardiac muscle and the correct functioning of the heart. This direct effect of CoQ10
on CVDs such as heart failure (HF) or myocardial infarction is accompanied by the crucial
action of CoQ10 as a potent antioxidant due to its coexistent redox forms (ubiquinone,
semi-ubiquinone and ubiquinol), which act in the mitochondrial membrane, other cell
membranes, and in plasma and cytoplasm. These antioxidant properties of CoQ10 act not
only on the electron transport chain in the mitochondria, but also in recycling other antioxi-
dants such as vitamin C or vitamin E. Along with its influence on the efficiency of energetic
metabolism, these other functions of CoQ10 have an important impact on cardiovascular
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health in humans, affecting the endothelial and vascular system, which in turn influences
the incidence, etiology, and progression of other CVDs such as coronary artery disease
(CAD) (Figure 1). For these reasons, we aimed to review the latest publications on the effect
of CoQ10 on cardiovascular health. In this review, we explore and analyze our current
knowledge of this issue and its future perspectives.
Figure 1. Pathogenic background of coenzyme Q10 in cardiovascular diseases. CoQ10: Coenzyme Q10; ATP: Adenosine
triphosphate; CAD: Coronary artery disease; HF: Heart failure; MI: Myocardial infarction; PAD: Peripheral artery disease;
ROS: Reactive oxygen species.
2. The Biology of CoQ10
CoQ10 is ubiquitous in all cell membranes, and is endogenously biosynthesized in
all tissues of the organism. A minor proportion of comes from dietary sources. However,
from a clinical point of view, it is noteworthy that endogenous production deficiency takes
part in the pathophysiology of different diseases, being that its biosynthesis is significantly
reduced with aging.
Endogenous CoQ10 biosynthesis is carried out by a pathway involving at least
11 genes, named COQ genes, which are well-conserved among species [6]. The first step in-
volves the benzoquinone ring being synthesized as 4-hydroxybenzoato and the isoprenoid
side chain precursor, acetyl-CoA [7,8]. In the context of CVDs, there is an important connec-
tion between CoQ10 biosynthesis and the action of one of the most common lipid-lowering
drugs, statins. Cholesterol biosynthesis shares a common pathway with CoQ10 endogenous
biosynthesis, which means that the use of statins in the treatment of hypercholesterolemia
leads to a reduction in the synthesis of CoQ10. This, in turn, results in a reduction in the
disposable supply of this compound, reducing the efficacy of energetic metabolism and
its implications in cardiac metabolism and redox status (Figure 2). Regarding the distribu-
tion of CoQ10 in the organism, it is known to be present in varying amounts in different
organs. Its levels range from 8 µg/g in the lung to 114 µg/g in the heart. Generally, it
is present more in tissues with high-energy requirements or metabolic activity such as
the heart, kidney, liver, and muscle [9]. However, CoQ10 levels are disrupted by health
and disease status. It has been reported that lesser amounts of CoQ10 are observed in
Alzheimer’s disease, cardiomyopathies, or type 2 diabetes mellitus compared to healthy
people [10,11].
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Figure 2. Coenzyme Q10 and cardiovascular diseases.
Another important factor in the biology and metabolism of CoQ10 is the bioavailability
and distribution of the different formulations of this compound when administered orally.
This is determined by its lipophilic characteristics, which make it extremely insoluble in
water. For this reason, the typical regimen of oral administration of CoQ10 takes advantage
of when lipid-rich foods are consumed [12]. In this context, many of the studies published
have failed to represent the real amount of CoQ10, which reaches the tissues, showing,
in most cases, the levels of this quinone measured in plasma, as a surrogate measurement
of the CoQ10 already ingested.
Despite these recommendations, research on CoQ10 absorption and bioavailability
varies, and is dependent on the type of CoQ10 preparation used [13,14]. Many formu-
lations have been developed to improve CoQ10 solubility in the organism. Recent new
formulations for CoQ10 are based on enhancing its water-solubility, as in the cases of Qter
or Ubisol-Q10. Ubisol-Q10 is a nanomiscelle formulation that appears to be water-soluble
containing CoQ10, where solubilization is achieved due to the amphipathic properties of
polyetilenglycol-derivatized α-tocopherol, which allows for the formation of stable and
water-soluble nanomicelles [15]. Q-ter is a supplement consisting of copovidone, which
acts as a carrier, CoQ10, and glycine, which works as a catalyst. This composition makes
Q-ter 200-times more soluble in water than pure CoQ10 [16].
Other efforts have been focused on discovering analogues of CoQ10 with greater solu-
bility and antioxidant effects such as MitoQ. MitoQ is also known as MitoQuinone (Phos-
phonium [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl] triphenyl-
,mesylate) and is a mitochondria-targeted antioxidant composed of a quinone moiety
attached to triphenylphosphonium (TPP) via a 10-carbon alkyl chain. The lipophilic nature
of TPP allows the antioxidant to be allocated in the mitochondrial matrix and accumulate
there [17]. However, there is very little literature on the use of these new formulations of
CoQ10 in randomized controlled trials (RCT) in CVDs, and most of them are in the field of
neurodegenerative diseases.
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3. Methodology of Review
CoQ10 has been extensively reviewed over the years. In this review, we planned to fo-
cus on CVDs and the most relevant findings published in the past five years. We performed
a search on PubMed on 31 January 2021 with the keywords “Coenzyme Q10 and cardio-
vascular diseases”. From the results of the search, we selected those diseases which were
more commonly represented among the studies from 2015, had been performed in humans,
and were predominantly in RCT. After revisiting this bibliography, we decided to include
the recent publications of studies on the influence of CoQ10 on cardiovascular risk fac-
tors (dyslipidemia, endothelial dysfunction, and hypertension), HF, myocardial infarction,
stroke, peripheral artery disease (PAD), and CAD. For each of these items, we performed
a new search on PubMed with “CoQ10/coenzyme Q10/ubiquinone cardiovascular risk
factors/dyslipidemia/endothelial dysfunction/hypertension/heart failure/myocardial in-
farction/stroke/peripheral artery disease/coronary artery disease”. From the publications
obtained in these searches, we selected those with the highest relevance.
4. CoQ10 and Cardiovascular Risk Factors
Different studies have examined the efficacy of CoQ10 supplementation in the pre-
vention of CVD through the reduction of cardiovascular risk factors (such as lipid and
lipoprotein levels, blood pressure or endothelial function) with the aim of improving
patient health and quality of life.
4.1. Dyslipidemias
Although the effect of CoQ10 supplementation on lipid and lipoprotein levels is
quantitatively small, different clinical studies, meta-analysis, and systematic reviews have
supported the beneficial effects in several types of patients for different CVD risks. In a
meta-analysis conducted by Sharifi et al. [18], the authors concluded that administration of
CoQ10 significantly reduced triglyceride (TG) concentrations, but not total cholesterol and
LDL-cholesterol levels in patients with metabolic disease. Similarly, Jorat et al. [19] found in
a meta-analysis that CoQ10 supplementation decreased total cholesterol and increased HDL-
cholesterol levels in patients with CAD. However, in a randomized, double-blind, placebo-
controlled study performed in obese participants, CoQ10 supplementation (200 mg/d
for 12-weeks) did not significantly affect lipid profiles [20]. In dyslipidemic subjects,
the administration of 120 mg/d of CoQ10 for 24-weeks reduced TG and LDL-cholesterol
concentrations and increased apolipoprotein A-1 compared to the placebo [21]. Results of a
double-blinded randomized clinical trial using 200 mg/d of CoQ10 for 12-weeks showed a
significant increase in HDL-cholesterol and a significant decrease in total cholesterol/HDL-
cholesterol ratio in patients with hyperlipidemia and myocardial infarction [22]. The total
cholesterol/HDL-cholesterol ratio is described as a significant predictor of cardiovascular
events and a therapeutic target in high-risk patients [23]. In patients with type 2 diabetes
and hyperlipidemia, CoQ10 increased the total cholesterol and LDL-cholesterol levels,
but had no effect on HDL-cholesterol compared with the placebo [24].
In the context of CAD, a recent systematic review found that CoQ10 supplementation
significantly decreased total cholesterol and increased HDL-cholesterol levels without af-
fecting TG and LDL-cholesterol [19]. Considering the fact that the use of statins to decrease
cholesterol synthesis also affects CoQ10 levels, the use of exogenous CoQ10 supplementa-
tion has been considered to preserve plasma CoQ10 levels in patients treated with these
therapeutic compounds (such as patients with CAD and HF) [25]. The combination of
CoQ10 with statins has been recently proposed to benefit hypercholesterolemic patients
with chronic heart failure [26,27]. In this context, in these patients, the co-administration
of CoQ10 and statin therapy is found to be highly recommendable to avoid myopathic
side effects as well as enhancing antioxidant enzymes activities and reducing inflamma-
tion [28,29]. An overview of the main evidence related to CoQ10 supplementation studies,
referred to in the text, is shown in Table 1 [16–77].
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Table 1. Coenzyme Q10 supplementation in recent studies in humans and its relation to cardiovascular disease.
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It has been suggested that CoQ10 could act, in the improvement of lipid and lipoprotein
profiles, through the activation of the gene expression of peroxisome proliferator-activated
receptor-gamma (PPAR-γ) [30], a nuclear receptor protein that regulates pathways related
to insulin, lipid metabolism, and inflammation [31] or via the AMP-activated protein ki-
nase/protein kinase C/NADPH oxidase signaling pathway, which suppresses oxidized
LDL-induced endothelial oxidative injuries by modulating oxidized low-density lipopro-
tein receptor 1-mediated reactive oxygen species (ROS) generation [32].
4.2. Hypertension
Hypertension is a key risk factor for almost all CVDs. Although many pharmacologi-
cal therapies have provided a beneficial effect in lowering blood pressure with a modest
decrease in cardiovascular mortality, hypertension remains prevalent [33,34]. Therefore,
the effect of CoQ10 on blood pressure has been studied in different controlled intervention
studies in human subjects, with a range of CoQ10 doses from 100 mg to 200 mg/day [35–37].
These studies found that patients treated with CoQ10 decreased both systolic and diastolic
blood pressure, without significant side effects [38]. In a systematic review performed in
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the context of primary prevention, the authors found that CoQ10 supplementation, without
lifestyle intervention, produced a significant reduction in systolic blood pressure without
an improvement in other CVD risk factors [39]. In a randomized, double-blinded con-
trolled clinical trial conducted in patients with hyperlipidemia and myocardial infarction,
CoQ10 supplementation (200 mg/d) for 12-weeks led to a decrease in both systolic and
diastolic blood pressure [22]. In fact, a recent review, in the context of primary prevention,
argued that CoQ10 could be used as an effective antihypertensive agent with a capacity of
lowering blood pressure to 11/7 [40]. However, in several studies conducted in patients
with ischemic left ventricular systolic dysfunction, type 2 diabetes mellitus or obesity,
but without hypertension, supplementation of CoQ10 did not alter blood pressure [20,41].
Strong evidence also points to a direct effect of CoQ10 on the endothelium by im-
proving vascular smooth muscle activity, counteracting vasoconstriction, and lowering
blood pressure [42]. Moreover, CoQ10 is also thought to provide a protective role in
hypertension, acting indirectly through its ability to prevent oxidative stress, nitrative
stress, and inflammation, resulting in a recoupling of endothelial nitric oxide synthase
(eNOS) [43].
4.3. Endothelial Dysfunction
Endothelial dysfunction, a main mechanism underlying the development of arte-
riosclerotic disease, is considered a significant predictor of cardiovascular risk [44,45].
The effect of CoQ10 supplementation on the modulation of endothelial function has been
evaluated in patients with type 2 diabetes mellitus, CAD, or in elderly people [46–48].
These results showed that flow-mediated dilation, or nitroglycerin-mediated dilation and
the extracellular superoxide dismutase activity increased in most of the subjects treated with
CoQ10, attributing this effect to its antioxidant and anti-inflammatory activity [35,48,49]. Al-
though the mechanisms of CoQ10 in modulating endothelial function are still unclear, it has
been suggested that it could be partly attributed to its capacity for reducing oxidative stress
and inflammation, particularly in myocardial and endothelial cells [50] and decreasing
the rate of activation of NO to peroxynitrite by superoxide radicals, which could improve
both vascular tone and endothelial function [51]. CoQ10 may also affect vascular function
indirectly via the inhibition of oxidative damage to LDL [43]. In fact, in patients with HF,
treatment with CoQ10 (400 mg/d for three months) resulted in significant improvements in
peripheral endothelial function, determined by the reactive hyperemia index, accompanied
by low levels of oxidized-LDL [52]. CoQ10 has also been shown to improve endothelial
function in patients with CAD [48] and type 2 diabetes mellitus [53].
Moreover, it has also been suggested that the protection of the endothelial function
through capturing blood plasma CoQ10 and thus reducing oxidative stress could play
a key role in the beneficial effect of plasma CoQ10 levels in CVD [46]. In fact, patients
with moderate dyslipidemia and endothelial dysfunction showed an improvement in their
cardiovascular status after treatment with CoQ10 [54]. Furthermore, the combined action of
CoQ10 and anti-atherogenic drugs such as statins improved endothelial dysfunction [55].
5. CoQ10 and CVDs
Cardiac tissues of patients with CVD (heart failure, angina pectoris, coronary artery
disease or cardiomyopathy) exhibited a strong CoQ10 deficiency [56,57]. Nutraceuticals
have been shown as effectively capable of reducing the burden of the atherosclerosis
process and CVD development, as already demonstrated in the literature [58]. In this
context, different studies have analyzed the effect of CoQ10 supplementation on CVD as a
therapeutic approach to reduce the clinical complications of CVD.
5.1. CoQ10 in Coronary Artery Disease
CAD is the most common type of heart disease. It is also known as coronary heart
disease or ischemic heart disease. In its etiology, CAD is caused by the formation of an
atherosclerotic plaque in the walls of the arteries that supply blood to the heart (coronary
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arteries) and other parts of the body. Due to the known involvement of oxidative damage
in the etiology of atherosclerosis, CoQ10 has been thought to have potential benefits in the
amelioration of CAD. Heng Lu et al. recently showed, in a correlation analysis of metabolic
pathways integrated as a unit to co-express susceptibility genes with CAD, that the canoni-
cal metabolic pathway of biosynthesis of CoQ10, specifically the genes COQ2 and COQ5,
were linked to the susceptibility of CAD [59]. The COQ2 gene encodes 4-hydroxybenzoate
polyprenyltransferase enzyme, which condenses decaprenyl pyrophosphate and 4-OH-
benzoate into decaprenyl-OH-benzoate [5,60]. The COQ5 gene encodes the enzyme that
catalyzes the only C-methylation step involved in the synthesis of CoQ10 [61]. Due to
the action of CoQ10 in energy metabolism and its relation to coronary revascularization,
some authors consider that low levels of CoQ10 should be considered as a risk factor for
CAD [62,63].
In a systematic review carried out by Jorat et al. in 2019, the authors looked for evi-
dence of effects of CoQ10 supplementation on inflammation and oxidative damage in CAD
patients [64]. Thirteen out of 912 potential RCT found in the literature were analyzed and it
was found that CoQ10 supplementation significantly increased the levels of the antioxidant
enzymes superoxide dismutase (SOD) and catalase, and significantly reduced malondi-
aldehyde (MDA), a marker of lipid peroxidation. Since CAD patients are considered to
have a chronic systemic inflammation status, this recent meta-analysis demonstrated the
potential benefits of CoQ10 supplementation for ameliorating inflammation and oxidative
damage in these patients. However, this analysis failed to demonstrate the effects of CoQ10
on C-reactive protein, tumor necrosis factor α, interleukin-6, and glutathione peroxidase
levels among patients with CAD, which have been described previously [28]. The dosage
range presented in the RCT included in the analysis was from 60 to 300 mg/day of CoQ10
with a follow-up of up to 48 weeks. However, no information was reported regarding the
formulation used for the supplementation. Since it has a great impact on the bioavailability
of CoQ10, and there seems to be a consensus that at least 200 mg/day is needed to have
an impact on rising plasma CoQ10 levels [5], there is a need for a RCT with these charac-
teristics to elucidate the real effects of CoQ10 on inflammatory and oxidative damage in
these patients.
5.2. CoQ10 in Heart Failure
Heart failure (HF) is defined as “a complex clinical syndrome that can result from any
structural or functional cardiac disorder that impairs the ability of the ventricle to fill or
eject blood” [65]. Despite improvements in the prevention and treatment of HF, mortality
rates from HF are over 10% per year, and even reach 20% to 50% in some settings [66].
In HF, the heart muscle exhibits reduced adenosine triphosphate synthesis, increased
production of ROS, and a deflection of the calcium exchange, mainly due to inefficient
electron transport chain activity. Moreover, in patients with HF, the severity of disease is
correlated with CoQ10 deficiency [67]. In this context, and since CoQ10 plays a key role in
cell energetics in the mitochondria, it is plausible to consider the potential benefits of CoQ10
supplementation as a therapeutic option for HF patients. It has also been demonstrated
that CoQ10 prevents senescence and dysfunction in vascular endothelial cells caused by
oxidative damage [51]. For this reason, supplementation with CoQ10 has been suggested
to prevent not only HF but also hypertension and endothelial dysfunction (see Section 4.3).
Over the last few years, several clinical studies have investigated the possibility
of using CoQ10 to prevent HF and improve the symptoms of this disease. In one of
the most important clinical studies related to this research area, the Q-SYMBIO study,
it was shown that in a study including 420 patients with moderate or severe HF (202
with 300 mg of CoQ10 supplementation and 218 with placebo), there was a reduction
in the rate of major adverse cardiac events, cardiovascular mortality, all-cause mortality,
and incidence of hospital stays for HF, after 2-years, compared to those patients treated
with the placebo [68]. However, the Q-SYMBIO study has been criticized, for instance,
for not reaching the planned number of patients (n = 550) in eight years of recruitment.
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Indeed, in a sub-group analysis of this study recently published, the researchers observed
improvements in major clinical endpoints, with an increase in left ventricular ejection
fraction in the European population of the study, which was not found in the larger cohort.
The authors declared that this subpopulation of the study showed a higher adherence
to the recommended medical and device therapies compared to the whole population.
Furthermore, the effects found in this study were confirmed in a subsequent meta-analysis
of 14 RCTs including 2149 patients, although no significant differences were observed in the
endpoint of left ventricular ejection fraction between the group that received treatment and
the group receiving a placebo [69]. However, short-term CoQ10 supplementation provided
no additional benefits in improving left ventricle diastolic function in 28 patients with
HF with preserved ejection fraction [70]. In general, the heterogeneity in the populations,
designs, follow-up durations, doses administered, and study outcomes make it difficult
to extract a clear effect of CoQ10 in HF. Nevertheless, there seems to be a consensus that
the beneficial effects attributable to CoQ10 in HF are related to its important role as an
electron carrier in mitochondria, increasing bioenergetics and preventing oxidative damage
in the failing myocardium. However, changes in the antioxidant systems in HF support the
idea that CoQ10 may improve the outcome and quality of life and may decrease morbidity
and mortality.
5.3. CoQ10 in Myocardial Infarction
Myocardial infarction occurs due to myocardial cell death caused by prolonged is-
chemia [71]. The pathologic processes underlying this disease are linked to a high oxidative
stress that leads to reperfusion-induced free radical damage, lipid peroxidation, and de-
creased energy production, in which CoQ10 deficiency could play a role [72,73]. In fact,
recent evidence has shown that maintaining high endogenous levels of CoQ10 in plasma,
in patients with myocardial infarction, is related to a better recovery of left ventricular
function [74]. In this context, another possible use for CoQ10 supplementation could be to
restore tissue CoQ10 deficiency in the myocardium after myocardial infarction. In a recent
RCT, the authors showed an improvement of quality of life in patients with myocardial
infarction using the MacNew QoL questionnaire, after 3-months of supplementation with
150 mg/d of CoQ10 plus 200 mg/d of L-carnitine [75]. Besides a reduction in blood pres-
sure, LDL-cholesterol/HDL-cholesterol and total cholesterol/HDL-cholesterol ratios in
patients who presented hyperlipidemia but also myocardial infarction, CoQ10 supplemen-
tation (200 mg/day for 12-weeks) also decreased inflammatory status (serum ICAM-1 and
IL-6 levels) [22,76]. In diabetic patients with CAD, CoQ10 supplementation also produced
an anti-inflammatory effect despite the fact that no improvement was observed in car-
diometabolic markers, suggesting that the presence of type 2 diabetes could infer different
underlying pathogenic mechanisms in myocardial infarction [77].
Regarding the possibility of using CoQ10 supplementation to prevent cardiac remodel-
ing in patients with myocardial infarction, in another study, 24-weeks of supplementation
of CoQ10 (120 mg/day) showed the maintenance of the sphericity index with diminished
alteration of wall-thickening abnormality at the infarct site, compared to the placebo,
in patients affected by persistent left ventricular dysfunction [78]. Moreover, in a recent
study performed in patients with myocardial infarction using 120 mg of CoQ10/day for
24-weeks, a protective role against left ventricular remodeling was observed in patients
with persistent left ventricular dysfunction [79].
5.4. CoQ10 in Peripheral Artery Disease
PAD is a common CVD characterized by the formation of atherosclerotic plaque
in the leg arteries, which causes attenuated blood flow and reduced perfusion in the
lower extremities [80]. PAD can severely impact quality of life as functional ability is
compromised as the disease progresses. Among the risk factors for the incidence of this
disease are smoking, diabetes mellitus and CAD, and age, with approximately 20% of the
population over 60 years presenting some degree of the condition. Symptoms often include
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claudication (leg pain during walking) and foot ulcers, which, if severe, may require
revascularization procedures or leg amputation [81].
In PAD, increased ROS appears as one of the mechanisms underlying atherosclerosis
and oxidative stress damage in the skeletal muscle [82]. At this point, maintaining an
effective function of the mitochondria in the vasculature is a key factor that controls ROS
production and NO bioavailability. In this context, mitochondria could be seen as a novel
therapeutic target to improve vascular function, oxygen transfer, and utility capacity in
the lower extremity, with a potential role in reducing leg pain and improving quality
of life in PAD patients [83]. Despite these premises, few studies have been published
that aim to evaluate the effect of CoQ10 supplementation in the amelioration of PAD.
Among recent publications, only one study with 11 PAD patients is worth mentioning.
In a randomized, placebo-controlled, crossover study design, patients received a dose of
80 mg of MitoQ, an analogue of CoQ10 [83]. The study aimed to understand the roles of the
vascular mitochondria in PAD in vivo by examining the impacts of acute MitoQ intake on
endothelial function, blood pressure, arterial stiffness, walking capacity, and oxygen utility
capacity in patients with PAD. The authors found, for the first time, an improvement in
brachial artery endothelial function after the intake of MitoQ, highlighting the key role
that vascular mitochondria plays in endothelial function in this kind of patient. Regarding
the molecular mechanisms behind these effects, Park S.Y. et al. showed an increase in
SOD, the first line of the endogenous antioxidant defense system, which could reduce
mitochondrial-derived ROS in the vasculature. In line with these findings, it seems to be of
importance to confirm the effects of CoQ10 in the amelioration of PAD in larger cohorts.
Despite the lack of clinical trials proving the benefits of CoQ10 supplementation, a recent
review summarized the nutrients that may be at risk of depletion in PAD patients treated
with lipid-lowering, antiplatelet, antihypertensive, and antidiabetic drugs. Among them,
the authors identified as potentially at risk from CoQ10, vitamin C, zinc, and vitamin
B12 [84]. As these medications are frequently prescribed to PAD patients, the authors
recommend that CoQ10, zinc, and vitamin B12 levels should be routinely monitored to
prevent and correct nutrient deficiencies associated with the multiple-drug therapy for
this condition. This leads to the possible need for dietary interventions, and the possible
supplementation with these nutrients in PAD patients.
5.5. Stroke
Stroke occurs when the blood supply to part of the brain is interrupted or reduced,
preventing the brain tissue from receiving oxygen and nutrients. Brain cells can only
survive a few minutes without this supply, and this leads to problems of ischemic brain
damage, which is extremely common in modern health care. In addition, ischemic stroke
has major socio-economic consequences, leading in some cases to disability in working-
age people. Oxidative stress has been described as one of the pathological mechanisms
involved in cerebral ischemia [85], where a disbalance among oxidants and antioxidants
causes further damage to cell structure and function [86]. Despite the evidence of the CoQ10
functions described, to the best of our knowledge, there are no recent publications in the
literature regarding clinical studies in humans considering the beneficial effect of CoQ10
supplementation to ameliorate the symptoms and consequences of stroke, although there is
one clinical study that aimed to associate CoQ10 levels with clinical neurological outcomes
in acute stroke patients [87]. This study found that stroke patients had significantly lower
serum levels of CoQ10 and SOD compared to the controls, and higher serum MDA levels,
in a cohort of 76 patients and 34 healthy individuals. The authors suggest that a decrease
in serum CoQ10 level exerts a detrimental effect on neurological outcomes following acute
ischemic stroke, as measured by the National Institute of Health Stroke Scale and a modified
Rankin Scale. Therefore, it can be suggested that preserving the antioxidant functionality
of CoQ10 could be a potential strategy in treating this pathology. On the other hand, there
is a more extensive bibliography, compared to human studies, on the influence of CoQ10
as a treatment in animal models. Although the scope of this review only includes human
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studies, it is interesting to note that Nikolaevna et al. recently found that intravenous
administration of CoQ10 led to a decrease in rat mortality rate, improvement in neurological
status and decrease in the brain necrosis area in acute and delayed periods after cerebral
ischemia [88]. Due to the lack of more clinical trials on the effect of pre- or post-treatment
with CoQ10 in strokes in larger human studies, we can only highlight the promising impact
this type of treatment could have on stroke patients.
6. Conclusions
Although the importance of CoQ10 can mostly be attributed to its function as an essen-
tial molecule for energy transduction in mitochondria, new findings support its relevant
function as an antioxidant, not only in mitochondria, but also in other cell compartments
and tissues in the organism as well as in plasma lipoproteins. Endogenous CoQ10 biosyn-
thesis supplies sufficient levels of this quinone in disease-free individuals. However, CoQ10
deficiency is not only based on genetic failure, but also on chronic and age-related diseases
such as CVDs. In this context, CoQ10 deficiencies have risen in CVDs, since statins, one of
the most common lipid-lowering drugs used in CVD patients, diminish endogenous CoQ10
biosynthesis because its initial steps are shared with the cholesterol biosynthesis pathway.
In this context, it has been shown that CoQ10 can potentially be used as a treatment to
ameliorate these deficiencies. However, the existence of various CoQ10 formulations, to-
gether with differences in the range of doses and periods of CoQ10 supplementation used
in the clinical studies, makes it difficult to compare them and reach a clear conclusion on
the most suitable dose, effectiveness, and bioavailability of oral-administration of CoQ10
for therapeutic use with CVDs. A major effort is needed to reach a consensus over the
use of this supplement, with the aim of including it in the clinical guidelines for treating
CVD patients.
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